Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo

Smith, C.A., Farrah, T. & Goodwin, R.G. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell 76, 959–962 (1994).

Cosman, D. A family of ligands for the TNF receptor superfamily. Stem Cells 12, 440–455 (1994).

Armitage, R.J. Tumor necrosis factor receptor superfamily members and their ligands. Curr. Opin. Immunol. 6, 407–413 (1994).

Peter, M.E., Ehret, A., Berndt, C. & Krammer, P.H. AIDS and the death receptors. Br. Med. Bull. 53, 604– 616 (1997).

Cohen, J. Cytokines as mediators of graft–versus–host disease. Bone Marrow Transplant. 3, 193–197 (1988).

Fisher, G.H. et al. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 81, 935–946 (1995).

Wiley, S.R. et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3, 673–682 (1995).

Griffith, T.S., Chin, W.A., Jackson, G.C., Lynch, D.H. & Kubin, M.Z. Intracellular regulation of TRAIL–induced apoptosis in human melanoma cells. J. Immunol. 161, 2833–2840.

Pitti, R.M. et al. Induction of apoptosis by Apo–2 ligand, a new member of the tumor necrosis factor cytokine family. J. Biol. Chem. 271, 12687–12690 (1996).

Mariani, S.M., Matiba, B., Armandola, E.A. & Krammer, P.H. Interleukin 1 β–converting enzyme related proteases/caspases are involved in TRAIL–induced apoptosis of myeloma and leukemia cells. J. Cell. Biol. 137, 221–229 (1997).

Pan, G. et al. An antagonist decoy receptor and a death domain–containing receptor for TRAIL. Science 277, 815– 818 (1997).

Pan, G. et al. The receptor for the cytotoxic ligand TRAIL. Science 276, 111–113 (1997).

Sheridan, J.P. et al. Control of TRAIL–induced apoptosis by a family of signaling and decoy receptors. Science 277, 818– 821 (1997).

Walczak, H. et al. TRAIL–R2: a novel apoptosis–mediating receptor for TRAIL. EMBO J. 16, 5386– 5397 (1997).

Degli–Esposti, M.A. et al. Cloning and characterization of TRAIL–R3, a novel member of the emerging TRAIL receptor family. J. Exp. Med. 186, 1165–1170 (1997).

Degli–Esposti, M.A. et al. The novel receptor TRAIL–R4 induces NF–κB and protects against TRAIL–mediated apoptosis, yet retains an incomplete death domain. Immunity 7, 813– 820 (1997).

Marsters, S.A. et al. A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr. Biol. 7, 1003– 1006 (1997).

Fanslow, W.C. et al. Structural characteristics of CD40 ligand that determine biological function. Semin. Immunol. 6, 267– 278 (1994).

Schneider, P. et al. Conversion of membrane–bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J. Exp. Med. 187, 1205–1213 (1998).

Ogasawara, J. et al. Lethal effect of the anti–Fas antibody in mice. Nature 364, 806–809 (1993).

Tanaka, M., Suda, T., Yatomi, T., Nakamura, N. & Nagata, S. Lethal effect of recombinant human Fas ligand in mice pretreated with Propionibacterium acnes. J. Immunol. 158, 2303–2309 (1997).

Revel, M. & Schattner, A. Interferons: cytokines in autoimmunity. Ciba. Found. Symp. 129, 223– 233 (1987).

Cerami, A. & Beutler, B. The role of cachectin/TNF in endotoxic shock and cachexia. Immunol. Today 9, 28–31 (1988).

Fiers, W. Tumor necrosis factor. Characterization at the molecular, cellular and in vivo level. FEBS Lett. 285, 199– 212 (1991).

Elliott, M.J. et al. Randomised double–blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344, 1105– 1110 (1994).

Moreland, L.W. et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)–Fc fusion protein. N. Engl. J. Med. 337, 141–147 (1997).

Zheng, L.X. et al. Induction of apoptosis in mature T cells by tumour necrosis factor. Nature 377, 348– 351 (1995).

Vandenabeele, P., Declercq, W., Vanhaesebroeck, B., Grooten, J. & Fiers, W. Both TNF receptors are required for TNF–mediated induction of apoptosis in PC60 cells. J. Immunol. 154, 2904–2913 (1995).

Brouckaert, P.G., Leroux–Roels, G.G., Guisez, Y., Tavernier, J. & Fiers, W. In vivo anti–tumour activity of recombinant human and murine TNF, alone and in combination with murine IFN–γ, on a syngeneic murine melanoma. Int. J. Cancer 38, 763–769 (1986).

Havell, E.A., Fiers, W. & North, R.J. The antitumor function of tumor necrosis factor d(TNF). I. Therapeutic action of TNF against an established murine sarcoma is indirect, immunologically dependent, and limited by severe toxicity. J. Exp. Med. 167, 1067–1085 (1988).

Alderson, M.R. et al. Fas ligand mediates activation–induced cell death in human T lymphocytes. J. Exp. Med. 181, 71–77 (1995).

Dhein, J., Walczak, H., Bäumler, C., Debatin, K.–M. & Krammer, P.H. Autocrine T–cell suicide mediated by APO–1/(Fas/CD95). Nature 373, 438–441 (1995).

Brunner, T. et al. Cell–autonomous Fas (CD95)/Fas–ligand interaction mediates activation–induced apoptosis in T–cell hybridomas. Nature 373, 441–444 (1995).

Ju, S.–T. et al. Fas(CD95)/FasL interactions required for programmed cell death after T–cell activation. Nature 373, 444–448 (1995).

Lowin, B., Hahne, M., Mattmann, C. & Tschopp, J. Cytolytic T–cell–cytotoxicity is mediated through perforin and Fas ligand pathways. Nature 370, 650–653 (1994).

Kägi, D. et al. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin–deficient mice. Nature 369, 31–37 (1994).

Galle, P.R. et al. Involvement of the CD95 (APO–1/Fas) receptor and ligand in liver damage. J. Exp. Med. 182, 1223– 1230 (1995).

Kondo, T., Suda, T., Fukuyama, H., Adachi, M. & Nagata, S. Essential roles of the Fas ligand in the development of hepatitis. Nature Med. 3, 409– 413 (1997).

Griffith, T.S., Brunner, T., Fletcher, S.M., Green, D.R. & Ferguson, T.A. Fas ligand–induced apoptosis as a mechanism of immune privilege. Science 270, 1189–1192 (1995).

Bellgrau, D. et al. A role for CD95 ligand in preventing graft rejection. Nature 377, 630–632 (1995).

French, L.E. et al. Fas and Fas ligand in embryos and adult mice: ligand expression in several immune–privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover. J. Cell. Biol. 133, 335–343 (1996).

Hahne, M. et al. Melanoma cell expression of Fas(Apo–1/CD95) ligand: implications for tumor immune escape. Science 274, 1363–1366 (1996).

Strand, S. et al. Lymphocyte apoptosis induced by CD95 (APO–1/Fas) ligand–expressing tumor cells—a mechanism of immune evasion? Nature Med. 2, 1361–1366 (1996).

Matiba, B., Mariani, S.M. & Krammer, P.H. The CD95 system and the death of a lymphocyte. Semin. Immunol. 9, 59–68 (1997).

Nagata, S. Apoptosis by death factor. Cell 88, 355– 365 (1997).

Emery, J.G. et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J. Biol. Chem. 273, 14363– 14367 (1998).